Inhaled Lidocaine for Refractory Neurogenic Cough
Inhaled lidocaine is an appropriate treatment option for refractory neurogenic cough that has failed gabapentin or amitriptyline, but it should be reserved as a later-line therapy after other neuromodulators have been exhausted. 1
Treatment Algorithm for Refractory Neurogenic Cough
First-Line: Neuromodulators
When gabapentin or amitriptyline have failed, you should:
Optimize the failed neuromodulator first - Ensure gabapentin was titrated to 1,800 mg/day in divided doses or amitriptyline to therapeutic levels before declaring failure 2
Switch to an alternative neuromodulator - If one neuromodulator fails, try another from this class before moving to lidocaine 3:
- If gabapentin failed → try amitriptyline
- If amitriptyline failed → try gabapentin
- Consider tramadol as third-line neuromodulator 3
Add multimodality speech pathology therapy concurrently with neuromodulators, as this combination addresses both neural sensitization and behavioral components 4, 2
Second-Line: Inhaled Lidocaine
Only after neuromodulators have been exhausted should you consider inhaled lidocaine. The evidence supporting this approach comes from lung cancer and palliative care guidelines, where lidocaine is positioned for opioid-resistant cough 1.
Practical Implementation:
Dosing regimen:
- Nebulized lidocaine 5 mL of 0.2% solution three times daily 1
- Alternative: Lidocaine throat spray (more effective than nebulization based on recent RCT data) 5
Critical safety precautions:
- Assess aspiration risk before initiating - Lidocaine causes oropharyngeal numbness and increases aspiration risk 1
- Administer first dose as inpatient to monitor for reflex bronchospasm 1
- Avoid food/drink for at least 1 hour after administration 1
- Pretreat with albuterol to prevent bronchospasm 6
- Monitor serum lidocaine levels if using chronic therapy (keep <4.0 mg/dL) 7
Expected effects:
- Throat spray shows greatest effect in first hour post-administration 5
- Common side effects: dysphonia, oropharyngeal numbness, bitter taste 8, 7
- Well-tolerated with minimal systemic effects when used appropriately 9, 8, 7
Evidence Quality and Nuances
The recommendation hierarchy reflects evidence strength:
- Gabapentin has Grade 2C recommendation from CHEST guidelines with RCT support showing quality-of-life improvement 2
- Morphine failed to pass guideline panel voting (only 75% approval vs 80% threshold needed), despite positive RCT data 2
- Lidocaine has consensus-based recommendation only for opioid-resistant cough in specific populations (lung cancer, palliative care) 1
The 2021 RCT by 5 provides the highest-quality evidence for lidocaine in refractory chronic cough, showing throat spray (but not nebulization) significantly reduced 10-hour cough frequency compared to placebo (22.6 vs 27.6 coughs/hour, P=0.04). However, this single study is insufficient to elevate lidocaine above neuromodulators in the treatment hierarchy.
Common Pitfalls to Avoid
Don't use lidocaine as first-line therapy - The CHEST unexplained chronic cough guidelines clearly prioritize gabapentin and speech therapy 2
Don't confuse "refractory" with "inadequately treated" - Verify proper dosing, compliance, and adequate trial duration (6 months for gabapentin) before declaring treatment failure 2
Don't overlook speech pathology - This non-pharmacologic intervention has comparable efficacy to medications and should be offered concurrently 4, 2
Don't ignore aspiration risk - This is the most serious safety concern with topical anesthetics and must be assessed before prescribing 1
When All Else Fails
If lidocaine also fails, consider:
- Low-dose opiates in palliative care setting with weekly then monthly reassessment 4
- Referral to specialized cough clinic for consideration of experimental therapies or clinical trials 2, 10
The FDA labeling for lidocaine explicitly states "NOT FOR INHALATION" for standard injectable formulations 11, so ensure you use appropriate formulations and document off-label use when prescribing for cough suppression.